Beneficial effect of additional treatment with widely available anticancer agents in advanced small lung cell carcinoma: A case report
- PMID: 30546895
- PMCID: PMC6256253
- DOI: 10.3892/mco.2018.1736
Beneficial effect of additional treatment with widely available anticancer agents in advanced small lung cell carcinoma: A case report
Abstract
Small-cell lung carcinoma is a type of lung cancer characterized by very poor prognosis, as the majority of the patients have already developed metastases at initial diagnosis. Small-cell lung cancer accounts for ~15% of all lung cancer cases. The present study reports the case of a female patient with advanced-stage small-cell lung cancer. The patient received the standard treatments (6 cycles of platinum and etoposide chemotherapy followed by Gamma Knife treatment of suspicious mediastinal lymphnodes); in addition, naturally derived agents (curcumin, parthenolide, betuline, sulforaphane, withanolides, lactoferrin, pomegranate fruit extract, flaxseed and dioscorea) were alternately administered at increased doses, while previously prescribed medications for other comorbidities (metformin and atorvastatin) were continued. Complete regression of the tumour was observed, and the patient remains in full remission and cancer-free for >7 years. Moreover, no treatment-related side effects and no drug interactions were observed.
Keywords: herbal substances; lung cancer.
Figures




Similar articles
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
-
Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.N Z Med J. 1998 Nov 27;111(1078):451-2, 453-4. N Z Med J. 1998. PMID: 9891564
-
Remission of Unresectable Lung Metastases from Rectal Cancer After Herbal Medicine Treatment: A Case Report.Explore (NY). 2016 Jul-Aug;12(4):259-62. doi: 10.1016/j.explore.2016.04.005. Epub 2016 Apr 16. Explore (NY). 2016. PMID: 27198037
-
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
-
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.Drugs R D. 2007;8(3):176-87. doi: 10.2165/00126839-200708030-00005. Drugs R D. 2007. PMID: 17472413 Review.
Cited by
-
Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies.Pharmaceuticals (Basel). 2020 Aug 14;13(8):194. doi: 10.3390/ph13080194. Pharmaceuticals (Basel). 2020. PMID: 32823992 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources